EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management
Connected insulin patch pump–Courtesy of Cellnovo Cellnovo Group ($CLNV) is already part of a major NIH trial for an artificial pancreas that incorporates its connected insulin pump-blood glucose monitor. Now, it’s joining a European Commission-sponsored R&D project to develop new technology aimed at Type 1 diabetics. Dubbed PEPPER (Patient Empowerment through Predictive Personalised decision support), the project is also being conducted with U.K. and European universities for better self-management of the disease. The three-year project is financed with almost €4 million ($4.5 million). “The Cellnovo diabetes management system is an ideal platform for a personalised decision support system because of its real-time connected data, as well as its wearability and discreetness,” said Cellnovo CEO Sophie Baratte in a statement. “The funding by the European Commission’s Horizon 2020 programme further demonstrates…
Link to Full Article: EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management
EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management
